急性心肌梗塞患者红细胞磷脂水平测定

本文测定了第１－７天急性心梗塞患者红细胞磷脂主要组分含量。结果表明，急性心肌梗塞患者红细胞膜的神经鞘磷含量较正常人明显增高；磷酯酰胆硷，磷脂酰丝氨酸、磷脂酰乙醇胺含量却较正常人明显降低。这说明急性心肌梗塞患者存在红细胞磷脂代谢紊乱，这时心肌缺血的重可能产生不良影响。     

兔心肌挫伤心功能障碍与心肌细胞内Ca2+和线粒体ATP酶的变化

目的：探讨心肌细胞内游离钙([Ca^2 ]i)和心肌ATP酶变化在心肌挫伤（MC）后心功能障碍发生机制中的意义。方法：随机选取兔36只，分为6组：正常对照、伤后2、4、8、12、24h，每组6只。经右颈总动脉插管至左心室测左室压力。采用BIM-II型生物撞击机致成MC模型。在上述时相点测定左室压力，并测定心肌细胞内[Ca^2 ]i和心肌匀浆组织及线粒体ATP酶活力。结果：心脏收缩/舒张功能受到损害，心肌细胞内[Ca^2 ]i升高，心肌匀浆组织及线粒体ATP酶下降，相关分析表明心功能障碍与心肌细胞内[Ca^2 ]i含量升高呈明显负相关，与ATP酶活性降低呈明显正相关。结论：MC后心脏功能下降，心肌细胞内[Ca^2 ]i含量升高和ATP酶活性下降可能是其原因之一。     

Role of Papillary Muscle Dysfunction in the Pathogenesis of Mitral Regurgitation in Myocardial Infarction:

To elucidate the pathogenesis of mitral regurgitation (MR) after myocardial infarction (MI), the incidence of papillary muscle dysfunction (PMD), mitral annular size, and the extent of wall-motion abnormalities were examined in 81 patients with previous MI by two-dimensional echocardiography and real-time two-dimensional Doppler flow imaging. The prevalence of pathological MR was lower in patients with anterior MI (36%) than in those with inferior (65%) or anterior and inferior MI (88%) (P < 0.01 vs anterior MI group). The incidence of PMD in patients with MR in the anterior MI group (15%) was lower than that in the inferior (50%, P < 0.01) or anterior and inferior MI group (43%, P < 0.05). The mitral annular dimension in patients with MR was significantly greater than in those without MR, but it was similar among the three groups. The extent of wall-motion abnormality correlated significantly with the area of MR jet in the anterior MI group (y = 3.1x + 15.5, r = 0.52, P < 0.01) and in the inferior MI group (y = 8.3x + 32.7, r = 0.57, P < 0.01). However, the slope of this relationship was significantly steeper in the inferior MI group than in the anterior MI group (P < 0.05). These results indicated that the degree of MR with inferior MI was greater than with anterior MI for a given MI area. PMD may play an important role in the higher prevalence and greater degree of MR in inferior MI.     

Assessment of myocardial viability in rats: Evaluation of a new method using superparamagnetic iron oxide nanoparticles and Gd-DOTA at high magnetic field.

The aim of this study was to detect salvageable peri-infarction myocardium by MRI in rats after infarction, using with a double contrast agent (CA) protocol at 7 Tesla. Intravascular superparamagnetic iron oxide (SPIO) nanoparticles and an extracellular paramagnetic CA (Gd-DOTA) were used to characterize the peri-infarction zone, which may recover function after reperfusion occurs. Infarcted areas measured from T1-weighted (T1-w) images post Gd-DOTA administration were overestimated compared to histological TTC staining (52% +/- 3% of LV surface area vs. 40% +/- 3%, P=0.03) or to T2-w images post SPIO administration (41% +/- 4%, P=0.04), whereas areas measured from T2-w images post SPIO administration were not significantly different from those measured histologically (P=0.7). Viable and nonviable myocardium portions of ischemically injured myocardium were enhanced after diffusive Gd-DOTA injection. The subsequent injection of vascular SPIO nanoparticles enables the discrimination of viable peri-infarction regions by specifically altering the signal of the still-vascularized myocardium.     

Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography

BACKGROUND: Electron beam tomography coronary calcium imaging is an evolving technique for the early detection of coronary atherosclerosis, and recent studies have established its prognostic value in asymptomatic individuals. The relationship of coronary artery calcium scores (CAC) to obstructive coronary artery disease (CAD) has been poorly studied but is clinically relevant because it determines which individuals are likely to benefit from revascularization procedures. Hence, we prospectively evaluated the prevalence of myocardial ischemia in asymptomatic patients with cardiovascular risk factors and subclinical atherosclerosis. METHODS AND RESULTS: We studied 864 asymptomatic patients with no previous CAD but with cardiovascular risk factors, referred for electron beam tomography coronary calcium imaging to our institution over an 18-month period. From this group, 220 consecutive patients (85% men; mean age, 61 +/- 9 years; age range, 31-84 years) with moderate to severe atherosclerotic disease (coronary calcium score > or =100 Agatston units) were prospectively evaluated by technetium 99m sestamibi single photon emission computed tomography (SPECT). Patients were followed up (mean follow-up, 14 months) and data regarding their subsequent clinical management recorded. Of the 220 patients, 119 had moderate atherosclerosis (CAC score of 100-400 Agatston units) and 101 had severe atherosclerosis (CAC score > or =400 Agatston units). Abnormal SPECT findings were seen in 18% of patients with moderate atherosclerosis (n = 21) and 45% of patients with severe atherosclerosis (n = 45). Increasing severity of atherosclerosis was related to increasing ischemic burden (summed difference score = 1 +/- 0.2 for CAC score of 100-400 Agatston units and 3.2 +/- 0.5 for CAC score > or =400 Agatston units). In a multivariate linear regression model incorporating risk factors, CAC was the only predictor of silent ischemia. CONCLUSION: In comparison to previously published data, we detected a higher prevalence of silent ischemia even in patients with moderate coronary atherosclerosis (18%). This may reflect the differing risk factor profile of our patient population. When coronary calcium screening is used to preselect asymptomatic patients with cardiovascular risk factors for myocardial perfusion imaging, the optimum coronary calcium score threshold will depend on the population prevalence of risk factors and asymptomatic obstructive CAD.     

大鼠心肌缺血再灌注时心肌细胞凋亡caspase-3活性变化规律及药物对其影响

目的　探讨大鼠心肌缺血再灌注 (Ischemiareperfusion ,IR)不同时相的心肌细胞凋亡、caspase 3活性变化规律及caspase 3抑制剂Ac DEVD CHO的影响。方法　Wistar大鼠 12 2只 ,设立IR组 ,IR +Ac DEVD CHO组和假手术对照组并分设缺血 3 0min后再灌注 1、3、6、12、2 4h 5个时相点 ;以缺口末端标记法 (TUNEL)标记凋亡细胞 ,用荧光分析法检测caspase 3活性 ,行TTC染色测定心肌梗死范围。结果　心肌细胞凋亡与caspase 3活性随心肌再灌注不同时相而变化 ,心肌细胞凋亡指数 (Apoptosisindex ,AI)与caspase 3活性于再灌注 12h最高 [AI :( 3 4 83± 9 3 5 ) % ;caspase 3活性 :( 1 3 4±0 2 ) ] ,其后基本维持在平台状态 ;心肌梗死范围随IR时间逐渐增加 ,至 2 4h仍未见下降趋势 ,三者间呈显著正相关 (P <0 0 5 )。IR +Ac DEVD CHO组上述指标虽也明显增高 ,但比IR组明显减小 (P <0 0 5 )。结论　Caspase 3激活及心肌细胞凋亡参与了心肌缺血再灌注损伤过程 ,Ac DEVD CHO减轻心肌缺血再灌注损伤可能部分与其抑制心肌细胞凋亡有关。     

急性心肌梗死后室间隔穿孔患者的外科治疗

目的:探讨急性心肌梗死(AMI)后室间隔穿孔(VSR)的外科治疗方法和结果。方法:回顾分析手术治疗的8例急性心肌梗死后室间隔穿孔患者的临床资料。男性7例,女性1例,年龄62～74岁,平均年龄67．5岁,均有急性心肌梗死史,4例有高血压病史,2例有糖尿病史,6例合并室壁瘤。心功能NYHAⅢ级6例,Ⅳ级2例。术前射血分数(EF)值33％～71％,平均54．5％。患者心肌梗死至手术的间隔时间平均为5．4周。所有患者均采用牛心包补片旷置室间隔穿孔,7例患者同期行冠状动脉旁路移植术,平均2．7支／例。结果:手术死亡2例,死亡率25％。其中1例因多脏器功能衰竭于术后32 d死亡,另1例因肾功能不全于术后6 d死亡。存活6例随访3～24个月,平均13．2个月,无晚期死亡,无心血管事件。心功能NYHAⅠ级5例,Ⅱ级1例。术后EF值50％～66％,平均58．3％。结论:掌握适当的手术时机、完善的术前准备、积极的围手术期治疗、准确的手术操作和避免术后并发症的发生,能有效地降低急性心肌梗死后室间隔穿孔患者的死亡率,改善其预后。     

重症心脏瓣膜置换术的体外循环管理

目的:回顾性总结重症心脏瓣膜病置换术体外循环经验.方法:105例重症心脏瓣膜病患者,使用stockerⅢ型心肺机及膜式氧合器,体外循环中采用中度低温,预充白蛋白并附加人工肾超滤,心肌保护用高钾含血停搏液灌注.结果:105例患者均顺利脱机,无1例死亡.体外循环时间60～180 min,主动脉阻断时间60～120 min,所有患者均顺利脱离体外循环,心脏自动复跳86例,电击19例.结论:手术中加强心肌保护,可减低手术后的功能衰竭和并发症,并可有效提高手术成功率.     

益气温阳活血方对急性心肌梗塞模型大鼠左室重构的影响

目的:观察益气温阳活血方对心肌梗塞模型大鼠左室重构的影响。方法:结扎冠脉前降支造模,治疗组益气温阳活血方灌胃,治疗第8周后检测各组大鼠心脏重量指数、左室壁面积、左室腔面积、左室腔周长等。结果:中药组心脏重量指数、左室壁面积、左室腔面积、和膨胀指数均较模型组下降(分别为P<0.05,P<0.01,P<0.05,P<0.01)。结论:益气温阳活血方具有良好的防治心室重构作用。     

Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes: a novel PET myocardial imaging agent

Background BMS-747158-02 is a novel fluorine 18-labeled pyridazinone derivative designed for cardiac imaging. The uptake and retention mechanisms of F-18 BMS-747158-02 in cardiac myocytes were studied in vitro, and the biodistribution of F-18 BMS-747158-02 was studied in vivo in mice. Methods and Results Fluorine 19 BMS-747158-01 inhibited mitochondrial complex I (MC-I) in bovine heart submitochondrial particles with an IC₅₀ of 16.6±3 nmol/L that was comparable to the reference inhibitors of MC-1, rotenone, pyridaben, and deguelin (IC₅₀ of 18.2±6.7 nmol/L, 19.8±2.6 nmol/L, and 23.1±1.5 nmol/L, respectively). F-18 BMS-747158-02 had high uptake in monolayers of neonatal rat cardiomyocytes (10.3%±0.7% of incubated drug at 60 minutes) that was inhibited by 200 nmol/L of rotenone (91%±2%) and deguelin (89%±3%). In contrast, an inactive pyridaben analog, P-0 (IC₅₀ value>4 μmol/L in MC-1 assay), did not inhibit the binding of F-18 BMS-747158-02 in cardiomyocytes. Uptake and washout kinetics for F-18 BMS-747158-02 in rat cardiomyocytes indicated that the time to half-maximal (t_1/2) uptake was very rapid (approximately 35 seconds), and washout t_1/2 for efflux of F-18 BMS-747158-02 was greater than 120 minutes. In vivo biodistribution studies in mice showed that F-18 BMS-747158-02 had substatial myocardial uptake (9.5%±0.5% of injected dose per gram) at 60 minutes and heart-to-lung and heart-to-liver ratios of 14.1±2.5 and 8.3±0.5, respectively. Positron emission tomography imaging in the mouse allowed clear cardiac visualization and demonstrated sustained myocardial uptake through 55 minutes. Conclusions F-18 BMS-747158-02 is a novel positron emission tomography cardiac tracer targeting MC-I in cardiomyocytes with rapid uptake and slow washout. These characteristics allow fast and sustained accumulation in the heart.